Ewopharma

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
Adenosine A3 receptor
MASH / NASHHepatocellular Carcinoma
Sugemalimab(Cejemly)
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
December 2029 (1)
Sugemalimab · CejemlyPhase 3Extranodal NK/T-cell Lymphoma
Est. primary completion 2029-12 · NCT05700448 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 April 2026Topline resultNamodenosonNamodenoson Phase 2a pancreatic cancer data announced

Financial reports

No financial reports recorded.